Opioid Addiction And COVID-19 Pandemic-Sourced Chronic And Acute Pain Targeted For Treatment By Electrotherapy Devices Such As WellnessPro Plus(TM) And Launch Planned For 2021 Of WellnessPro(R) Pod By

November 6, 2020 8:15 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Opioid addiction caused by prescriptions for pain killer pharmaceuticals and COVID-19 Pandemic-sourced pain from stress and canceled health treatment visits has been targeted and effectively treated by drug-free electrotherapy treatments. In an opioid-free and non-addictive environment, bioelectronic treatment focuses on various chronic, acute, post-traumatic and intractable pain. Companies like Electromedical Technologies, Inc. (OTCQB: EMED) and Nevro Corp. (NYSE: NVRO) are offering bioelectronic devices for alternative and non-addictive treatment.

The chronic pain treatment market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT), Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM). GlaxoSmithKline (NYSE: GSK), Abbott Laboratories (NYSE: TBA), Eli Lilly (NYSE: LLY), Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).

Opioid Addiction And COVID-19 Pandemic-Sourced Chronic And Acute Pain Targeted For Treatment By Electrotherapy Devices Such As WellnessPro Plus(TM) And Launch Planned For 2021 Of WellnessPro(R) Pod By Electromedical Technologies, Inc. (OTCQB: EMED); Nevro Corp. (NYSE: NVRO) Offers HF10(TM) To Alleviate Pain

At the forefront of future medicine, Electromedical Technologies, Inc. (OTCQB: EMED) is a leader in this field of addressing acute and chronic pain with its line of FDA cleared WellnessPro Plus(TM) devices and scheduled launch in 2021 of its wearable WellnessPro(R) Pod. The Company is collaborating with numerous universities and schools to research the field of bioelectronics. It is seeking to develop a program to study the effects of electro-modulation on the human body, especially cell signaling and virus assembly and immune responses. The goal is human well being with a focus on doctors sending home patients with Pods rather than bottles of potentially-addictive opioid pharmaceutical drugs.

Avoiding Painkiller Pharmaceuticals And Opioid Addictions

The WellnessPro Plus(TM) is a non-invasive device delivering electrotherapy treatment for chronic and acute pain. Its use avoids painkillers and the opioid addictions that can result. The WellnessPro(R) Pod scheduled for market launch next year is wearable. The COVID-19 pandemic has been long-lasting and been the source of various anxiety and stress disorders, causing pain to patients. Opioid Addiction And COVID-19 Pandemic-Sourced Chronic And Acute Pain Targeted For Treatment By Electrotherapy Devices Such As WellnessPro Plus(TM) And Launch Planned For 2021 Of WellnessPro(R) Pod By Electromedical Technologies, Inc. (OTCQB: EMED); Nevro Corp. (NYSE: NVRO) Offers HF10(TM) To Alleviate Pain.

A Neuro-Modulation Platform

Nevro Corp. (NYSE: NVRO) offers its HF10(TM) implanted device to alleviate pain, particularly addressing the effectiveness of calming nerves for patients suffering from back and leg pain. The HF 10(TM) therapy is a neuro-modulation platform which relies on an implanted device which uses Spinal Cord Stimulation (SCS) science. It is designed to use mild electrical pulses to the spinal cord, with the goal of calming the nerves and reducing pain signals to the brain. Opioid Addiction And COVID-19 Pandemic-Sourced Chronic And Acute Pain Targeted For Treatment By Electrotherapy Devices Such As WellnessPro Plus(TM) And Launch Planned For 2021 Of WellnessPro(R) Pod By Electromedical Technologies, Inc. (OTCQB: EMED); Nevro Corp. (NYSE: NVRO) Offers HF10(TM) To Alleviate Pain.

Electromedical Technologies, Inc. (OTCQB: EMED) Collaborating With Universities And Schools To Research The Field And Establish Certification And Training Programs

EMED is also collaborating with more universities and colleges to R&D and certify therapists in this field to raise the profile of bioelectronics and its available non-opioid treatments. In addition to its existing relationships with universities and schools, Electromedical Technologies, Inc. (OTCQB: EMED) announced recently that it had reached agreement to collaborate with the Energetic Wellness School of Naturopathy, located in Oklahoma, to develop a new distribution platform and certification training program for "Bioelectronics Therapist and Master Device Technician." The certification program and curriculum are pending approval, the School said. Opioid Addiction And COVID-19 Pandemic-Sourced Chronic And Acute Pain Targeted For Treatment By Electrotherapy Devices Such As WellnessPro Plus(TM) And Launch Planned For 2021 Of WellnessPro(R) Pod By Electromedical Technologies, Inc. (OTCQB: EMED); Nevro Corp. (NYSE: NVRO) Offers HF 10(TM) To Alleviate Pain.

A 'Hands On' Understanding Of The Benefits Of Electrotherapy Treatment

Matthew Wolfson, founder and CEO of Electromedical Technologies, Inc. (OTCQB: EMED), said, "Doctors and students will have access to the Wellness Pro(R) Plus devices, which will give them a hands on understanding of the various techniques and benefits of using drug free application techniques for chronic, acute post traumatic and intractable pain."

Electromedical Technologies, Inc. (OTCQB: EMED) Planning Wellness Pro(R) Pod

Electromedical Technologies, Inc. (OTCQB: EMED) is a commercial stage company marketing a line of FDA cleared devices for the treatment of chronic acute post traumatic and post-operative, intractable pain relief. The Company is planning to launch another device in 2021, the WellnessPro(R) Pod. It is collaborating with universities and colleges to establish a comprehensive research program that defines the effects of electro-modulation on the human body.

Chronic Pain Treatment Market Projected To Reach $151.7 Billion By 2030

Research firm Prescient & Strategic Intelligence sees the chronic pain treatment market hitting $151.7 Billion by 2030, reflecting a CAGR of 6.5%% during the forecast period from 2020-2030. The pandemic accelerated the opioid epidemic crisis in the research period. The report finds that North America dominates the global chronic pain market. Opioid Addiction And COVID-19 Pandemic-Sourced Chronic And Acute Pain Targeted For Treatment By Electrotherapy Devices Such As WellnessPro Plus(TM) And Launch Planned For 2021 Of WellnessPro(R) Pod By Electromedical Technologies, Inc. (OTCQB: EMED); Nevro Corp. (NYSE: NVRO) Offers HF10(TM) To Alleviate Pain.

Source: Stock Market Press

Join Stock Market Press' newsletter for the latest in IPO, market commentary and company profiles.

Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.

Contact:

Stock Market Press
110 Wall St.
New York, NY 10005 [email protected] Safe Harbor Statement:

Statements in this news release may be "forward-looking statements." Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

See Stock Market Press disclaimer: http://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press

comtex tracking

COMTEX_374043655/2677/2020-11-06T08:12:52

Is there a problem with this press release? Contact the source provider Comtex at [email protected].



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Press Releases, Stock Market Press

Related Entities

IPO, FDA